Modern approaches to diagnosis and treatment of syndrome of autonomic dysfunction in children

Close metadata

Recommended articles:

Tooth decay and autism spectrum disorders in children: is there a connection?. Stomatology. 2024;(2):71-76

The results of vital pulpotomy in primary teeth in children with negative behavior. Stomatology. 2024;(2):77-79

Clinical and laboratory features of subclinical hypothyroidism in 7—12 years old children. Russian Journal of Preventive Medicine. 2024;(5):53-59

Choanoplasty in children of the first year of life: new opportunities and rehabilitation without stents. Russian Bulletin of Otorhinolaryngology. 2024;(2):40-45

Halotherapy in rehabilitation of children. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):37-44

Endotypes of chronic rhinosinusitis in children. Russian Rhinology. 2024;(2):82-88

Nissen robot-assisted fundoplication in a child with gastroesophageal reflux. Endoscopic Surgery. 2024;(3):41-47

Risk factors for the iron deficiency anemia development in infants: pylot study. Russian Journal of Preventive Medicine. 2024;(6):53-59

Hydrogen sulfide balneotherapy in comprehensive sanatorium-resort treatment of post-burn scars in children. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(3):32-40

Endometriosis and genital malformations in children and adolescents. What do they have in common?. Russian Journal of Human Reproduction. 2024;(3):14-22

The article is devoted to the important problem of diagnosis and treatment of children with autonomic dysfunction syndromes (SVD). Information is provided on the evolution of views on the pathogenesis of this condition. The issues of pathogenesis, classification and clinical manifestations of SVD in children and adolescents are covered in detail. The high effectiveness of the use of Mexidol in the complex correction and prevention of manifestations of SVD, as well as concomitant neuropsychiatric disorders in children and adolescents has been demonstrated.

Keywords:

vegetative disorders

autonomic dysfunction syndrome

children

Mexidol

Authors:

Nemkova S.A.

Pirogov Russian National Research Medical University (Pirogov University)

ORCID: 0000-0002-9679-9640

Received:

13.09.2024

Accepted:

16.09.2024

List of references:

Vegetativnye rasstrojstva: klinika, diagnostika, lechenie. Pod red. A.M. Vejna. M.: Medicinskoe informacionnoe agentstvo. 2000. (In Russ.).
Belokon’ NA, Osokina GG, Leont’eva IV. Vegetososudistaya distoniya u detej: klinika, diagnostika, lechenie: metodicheskie rekomendacii. M., 1987. (In Russ.).
Karvasarskij BD. Nevrozy: rukovodstvo dlya vrachej. M.: Medicina, 1980. (In Russ.).
Zavadenko NN, Nesterovskij YuE. Clinical manifestations and treatment of autonomic dysfunction syndrome in children and adolescents. Pediatriya. 2012;91(2):92-101. (In Russ.).
Chutko LS, Surushkina SYu, Yakovenko EA. Clinical and psychophysiological manifestations of dyscalculia in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;118(1):43-49. (In Russ.). https://doi.org/10.17116/jnevro202212209262
Nemkova SA, Semenov DV, Petrova EA, et al. Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):35-42. (In Russ.). https://doi.org/10.17116/jnevro201911907127
Sindrom vegetativnoj disfunkcii u detej: uchebnoe posobie. Federal’noe agentstvo po zdravoohraneniyu i social’nomu razvitiyu RF, GOU VPO «Izhevskaya gosudarstvennaya medicinskaya akademiya». Kafedra detskih boleznej FPK i PP; sostavitel’ M.M. Toropova. Izhevsk: IGMA, 2008. (In Russ.).
Efimova NV, Mel’nikova IV. On the influence of environmental and lifestyle factors on the formation of autonomic dysfunction syndrome in schoolchildren. Gigiena i Sanitariya. 2019;98(1):76-81. (In Russ.).
Chutko LS, Nemkova SA. Symptoms and masks. Psychosomatic and somatopsychic disorders in children. Effektivnaya Farmakoterapiya. 2019;14:30-37. (In Russ.).
Chekalova SA. Syndrome of vegetative dystonia in high school students. Remedium Privolzh’e. Ohrana Zdorov’ya Materi i Rebenka. 2006;136-137. (In Russ.).
Kuzmichev YuG, Kuz’mina NA, Chekalova SA, et al. Prevalence, structure and risk factors of vegetative dystonia syndrome in high school students. Nizhegorodskij Medicinskij Zhurnal. 2006;8:260-262. (In Russ.).
Okuneva MA. The use of mexidol in the correction of the syndrome of autonomic dysregulation as a consequence of perinatal lesions of the central nervous system. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2012;1:200-204. (In Russ.).
Nemkova SA. Modern principles of integrated diagnostics and rehabilitation of perinatal lesions of the nervous system and their consequences. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3):40-49. (In Russ.). https://doi.org/10.17116/jnevro20171173140-49
Classification of perinatal lesions of the nervous system and their consequences in children of the first year of life. Methodological recommendations. Edited by N.N. Volodin. M.: VUNMC; 2006. (In Russ.).
Rossijskij statisticheskij ezhegodnik: statisticheskij sbornik. M.: Federal’naya sluzhba gosudarstvennoj statistiki. 2021. (In Russ.).
Ladodo KS. Respiratornye virusnye infekcii i porazhenie nervnoj sistemy u detej. M.: Medicina, 1972. (In Russ.).
LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021;78(5):536-547. https://doi.org/10.1001/jamaneurol.2021.0504
Nemkova SA. Neurological aspects of the consequences of COVID-19 in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(4):23-30. (In Russ.). https://doi.org/10.17116/jnevro202212204123
Shtok VN, Levin OS. Spravochnik po formulirovaniyu klinicheskogo diagnoza boleznej nervnoj sistemy. M.: Medicinskoe informacionnoe agentstvo, 2013. (In Russ.).
Yakhno NN, Smulevich AB, Terluin B, et al. The primary screening of patients with autonomic disorders in outpatient clinics In Russia (START1) using the Russian version of The Four-Dimensional Symptom Questionnaire (4DSQ). S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(12):112-122. (In Russ.). https://doi.org/10.17116/jnevro2014114121112-122
Majdannik VG. Osnovy klinicheskoj diagnostiki v pediatrii. Kiev, 1998. (In Russ.).
Chekalova SA. Monitoring of the somatic status of schoolchildren with pathology of the nervous system living in a large industrial city. Nevrologicheskij Vestnik. 2008;40(2):99-100. (In Russ.).
Chekalova SA, Bogomolova ES, Leonov AV, et al. Features of the somatic status in schoolchildren with vegetative dystonia syndrome. Rossijskij Pediatricheskij Zhurnal. 2009;6:41-43. (In Russ.).
Rodionova EYu, Chutko LS, Krotin PN. Psychoautonomic disorders in girls with impaired development of menstrual cycle. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(12):30-33. (In Russ.). https://doi.org/10.17116/jnevro201611612130-33
Thiele W. Psycho-vegetative Syndrome. Ment. Welt. 1966;1(9):9-14.
Nesterovskij YuE, Zavadenko NN, Shipilova EM. Primary headaches in children: diagnosis and principles of treatment. Consilium Medicum. 2019;21(9):74-80. (In Russ.).
Chekalova SA, Kuzmichev YuT, Leonov AV, et al. Assessment of students’ well-being based on the results of a questionnaire test survey. Voprosy Sovremennoj Pediatrii. 2005;4(1):58-62. (In Russ.).
Chekalova SA, Bogomolova ES, Leonov AV, et al. Features of physical development in high school students with vegetative dystonia syndrome. Vestnik Sankt-Peterburgskoj Gosudarstvennoj Medicinskoj Akademii im. I.I. Mechnikova. 2009;31(2):43-45. (In Russ.).
Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
Voronina TA. Mexidol. The main neuropsychotropic effects and mechanism of action. Farmateka. 2009;6:35-38. (In Russ.).
Voronina TA. Mexidol: the spectrum of pharmacological effects. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):86-90. (In Russ.).
Voronina TA. Pioneer of antioxidant neuroprotection. 20 years in clinical practice. RMZh. 2016;24(7):434-438. (In Russ.).
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Chukhlovina ML, Chukhlovin AA. Features of the patient management with traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):145-151. (In Russ.). https://doi.org/10.17116/jnevro2021121091145
Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro20161164128-31
Robertson D, Haile V, Perry SE, et al. Dopamine betahydroxylase deficiency: a genetic disorder of cardiovascular regulation. Hypertension. 1991;18:1-8.
Vorsin LP. Pokazateli EEG and HRV indices in patients with dysfunction of the suprasegmental parts of the autonomic nervous system: the experience of using Mexidol. Byulleten’ eksperimental’noj biologii i mediciny. 2012;1:172-176. (In Russ.).
Manegold C, Hoffmann GF, Degan I, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow up. Journal of inherited metabolic disease. 2009;32:371-380. https://doi.org/10.1007/s10545-009-1076-1
Miroshnichenko II, Smirnov LD, Voronin AE, et al. Vliyanie Mexidola na soderzhanie mediatornyh monoaminov i aminokislot v strukturah golovnogo mozga krys. Byulleten’ Eksperimental’noj Biologii i Mediciny. 1996;2:170-173. (In Russ.).
Gromova OA, Torshin IYu, Sorokin AI, et al. Chemotranscriptome analysis of the ethylmethylhydroxypyridine succinate molecule in the context of postgenomic pharmacology. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):130-137. (In Russ.). https://doi.org/10.14412/2074-2711-2020-5-130-137
Tepaev DV. Investigation of the possibility of pharmacological correction of vegetative and immune disorders with mexidol in individuals with signs of vegetative changes. Byulleten’ Eksperimental’noj Biologii i Mediciny, 2006;(1):90-96. (In Russ.).
Nemkova SA. Current possibilities of complex diagnosis and treatment of the consequences of traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10):94-102. (In Russ.). https://doi.org/10.17116/jnevro201911910194
Ignatova AV. Opyt primeneniya preparata Mexidol v lechenii postkommocionnogo sindroma u lic molodogo s srednego vozrasta v ambulatornyh usloviyah. Terapiya. Mexidol v nevrologii. 2019;23(6):23-28. (In Russ.).
Ignatova AV. The experience of using mexidol in the treatment of concussion and in the late recovery period after severe traumatic brain injuries. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2012;23(1):34-38. (In Russ.).
Zavadenko NN, Suvorinova NYu, Zavadenko AN. The possibilities of Mexidol usage in neuropediatrics. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9-2):43-50. (In Russ.). https://doi.org/10.17116/jnevro202312309243
Hamitova GR. Primenenie preparata «Mexidol» v detskoj nevrologicheskoj praktike. MEXIDOL: obobshchenie opyta klinicheskogo primeneniya. Nevrologiya. 2012;34(3):100-101. (In Russ.).
Klinicheskie rekomendacii po vedeniju detej s posledstvijami perinatal’nogo porazhenija central’noj nervnoj sistemy s sindromom myshechnogo gipotonusa. (In Russ.). https://www.pediatr-russia.ru/information/klin-rek/deystvuyushchie-klinicheskie-rekomendatsii/index.php
Zavadenko NN, Suvorinova NYu, Batysheva TT, et al. Results of a multicentre double-blind randomised placebo-controlled clinical trial evaluating the efficacy and safety of Mexidol in the treatment of Attention Deficit Hyperactivity Disorder in Children (MEGA). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(4):75-86. (In Russ.). https://doi.org/10.17116/jnevro202212204175
Levitina EV, Petrushina AD. Pathogenetic justification of the use of Mexidol in the treatment of hypoxic-ischemic encephalopathy in newborn children. Rossijskij Pediatricheskij Zhurnal.2001;6:4-8. (In Russ.).
Askerova DM. The use of Mexidol in newborns with intrauterine growth retardation syndrome in the correction of hypoxic-ischemic lesions of the central nervous system. Uspekhi Sovremennogo Estestvoznaniya. 2011;5:50-52. (In Russ.).
Barhatov MV, Bochkun-Zharikova AV, Viktorova GI, et al. Obosnovannost’ primeneniya preparata Mexidol u detej s posledstviyami gipoksicheskih perinatal’nyh encefalopatij. Pervyj opyt primeneniya preparata Mexidol v pediatricheskoj praktike. M., 2005;25-32. (In Russ.).
Zvonareva EV. Comparison of the effect of Mexidol and pantocalcin on the clinical and functional manifestations of posthypoxic encephalopathy in young children. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2012;1:237-239. (In Russ.).
Hajretdinova TB. The effectiveness of the use of Mexidol in young children operated on for congenital heart defects at the stages of their rehabilitation. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2012;1:240-245. (In Russ.).
Dobrazova OP, Dobrazova DA. Mexidol in the treatment of cognitive disorders in adolescents with asthenic syndrome. Terapiya, Specvypusk. Mexidol v Nevrologii. 2019;21(3):97-100. (In Russ.).

Close metadata